<DOC>
	<DOCNO>NCT00427583</DOCNO>
	<brief_summary>This study assess safety efficacy imatinib mesylate treatment patient malignant peripheral nerve sheath tumor</brief_summary>
	<brief_title>Imatinib Mesylate Treatment Patients With Malignant Peripheral Nerve Sheath Tumors</brief_title>
	<detailed_description />
	<mesh_term>Nerve Sheath Neoplasms</mesh_term>
	<mesh_term>Neurofibroma</mesh_term>
	<mesh_term>Neurilemmoma</mesh_term>
	<mesh_term>Neurofibrosarcoma</mesh_term>
	<mesh_term>Imatinib Mesylate</mesh_term>
	<criteria>Inclusion criterion : Patients â‰¥18 year age Histologically document diagnosis malignant MPNST Unresectable local MPNST metastatic MPNST therefore incurable conventional multimodality approach Life expectancy least 6 month . Exclusion criterion : Patient receive investigational agent within 28 day first day study drug dose . Chemotherapy radiotherapy last 6 week study entry , surgery last 14 day study entry . Female patient pregnant breast feed woman child bear potential use highly effective method birth control . Known CNS metastases Other protocoldefined inclusion/exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>Malignant ,</keyword>
	<keyword>peripheral ,</keyword>
	<keyword>nerve sheath tumor ,</keyword>
	<keyword>MPNST ,</keyword>
	<keyword>neurofibromatosis ,</keyword>
	<keyword>NF1 ,</keyword>
	<keyword>Imatinib mesylate</keyword>
</DOC>